Aktiia secures CHF 27 Million
Share this article
The Neuchâtel-based startup secures CHF 27 Million (USD 30M) in funding from Khosla Ventures and Others.
Aktiia mission to revolutionise blood pressure monitoring has gained momentum with the successful closing of our CHF 27 million (USD 30 million) funding round, which was led by Redalpine and included participation from an international investor syndicate that included Khosla Ventures, Molten Ventures, Translink Capital, Verve Ventures and 415 Capital.
This strategic infusion of capital will accelerate Aktiia’s mission to ease the global burden of hypertension by providing groundbreaking insights into blood pressure management through AI-driven technology, currently used by over 60,000 customers and dozens of healthcare organisations.
A new President for Aktiia
In conjunction with this funding, Aktiia welcomes Daniel Graf as its new President and Board Member. Daniel, a seasoned technology executive with a distinguished career at companies like Uber and Google, brings a wealth of experience in entrepreneurship, product innovation, and scaling businesses.
His leadership will be instrumental in guiding Aktiia’s strategic direction and expansion, as the company continues to pioneer advancements in hypertension management.
“Aktiia’s commitment to transforming the way blood pressure is treated and understood aligns perfectly with my passion for leveraging technology to address pressing healthcare challenges,” said Daniel Graf. “I am excited to join this talented team and contribute to a future where hypertension management is more proactive, data-driven, personalised, and effective.”
Aktiia’s CE-marked device is currently available in seven European markets and approved as a medical device in 44 countries worldwide. Aktiia’s technology provides unparalleled innovation and ease in blood pressure data collection and machine learning modelling. It offers personalised, continuous, and medical-grade blood pressure and heart rate data.
Source: press release